Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse

Telix Pharmaceuticals has announced a strategic merger agreement to acquire ITM Isotope Technologies Munich for $1.65 billion upfront, with up to $700 million in contingent consideration. The merger combines Telix's therapeutic pipeline with ITM's world-leading radioisotope production capabilities and ITM-11 (177Lu-edotreotide), a Phase 3-completed candidate for neuroendocrine tumors. The combined entity is expected to generate over $1.3 billion in pro forma 2026 revenue and achieve positive EBITDA by 2027.